WALPOLE PHARMACEUTICALS LIMITEDActive

Company number 04843395Private limited companyIncorporated 2003

Key figures

£118,276+52.3%
Net assets 2024/25
-11.7%
Average annual change 2020/21–2024/25
050 k100 k150 k200 k2020/212021/222022/232023/242024/25

Like most small UK companies, WALPOLE PHARMACEUTICALS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0200 k400 k600 k2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand65,591102,16140,68420,47030,644
Total assets436,885404,713327,452303,586344,347
Total liabilities241,981214,368212,541225,920226,071
Net assets / total equity194,904190,345114,91177,666118,276
Average number of employees67097

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: WALPOLE PHARMACEUTICALS LIMITED

Company

WALPOLE PHARMACEUTICALS LIMITED is a private limited company registered with Companies House under company number 04843395. It was incorporated on 23 Jul 2003. Its status is active. The registered office is in London (W6). Its nature of business (SIC 2007) is dispensing chemist in specialised stores (47730).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files small company accounts (filleted). Net assets were £118,276, up 52.3% on the previous year. Cash at bank and in hand was £30,644. Total assets were £344,347 and total liabilities £226,071. The company had an average of 7 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

One person with significant control is registered. 1 of 3 registered charges are outstanding.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 6 Aug 2027.